GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) and published in the journal Pharmaceutics.
This article was originally published on MedicalXpress.com